Biomarkers and clinical staging in psychiatry

World Psychiatry

Volumn 13, Issue 3, 2014, Pages 211-223

  McGorry, Patrick ^a   Keshavan, Matcheri ^b   Goldstone, Sherilyn ^a   Amminger, Paul ^a   Allott, Kelly ^a   Berk, Michael ^a,c   Lavoie, Suzie ^a   Pantelis, Christos ^d   Yung, Alison ^e   Wood, Stephen ^f   Hickie, Ian ^g  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biomarkers; Clinical staging; Diagnostic reform; Early intervention; Personalized medicine; Pre emptive psychiatry; Youth mental health

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; FATTY ACID; N METHYL DEXTRO ASPARTIC ACID; OMEGA 3 FATTY ACID;

ARTICLE; BRAIN FUNCTION; CHRONIC DISEASE; CHRONOBIOLOGY; COGNITION; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; EARLY INTERVENTION; ENVIRONMENTAL FACTOR; HARM REDUCTION; HUMAN; INTEGRATION; LIPID METABOLISM; MAJOR DEPRESSION; MENTAL DISEASE; MENTAL HEALTH; META ANALYSIS (TOPIC); MISMATCH NEGATIVITY; MOTIVATION; NEUROIMAGING; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PROPHYLAXIS; PSYCHIATRY; PSYCHOSIS; RISK; SLEEP; SOCIAL ASPECT;

EID: 84908115819     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20144     Document Type: Article

References (174)

1. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-93.
2. McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am J Psychiatry 2007;164:859-60.
3. McGorry PD, Nelson B, Goldstone S et al. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry 2010;55:486-97.
4. McGorry PD. The next stage for diagnosis: validity through utility. World Psychiatry 2013;12:213-5.
5. Bertelsen M, Jeppesen P, Petersen L et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry 2008;65:762-71.
6. Hegelstad WT, Larsen TK, Auestad B et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry 2012;169:374-80.
7. Norman RM, Manchanda R, Malla AK et al. Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophr Res 2011;129:111-5.
8. Insel T. The arrival of preemptive psychiatry. Early Interv Psychiatry 2007;1:5-6.
9. Wigman JT, van Os J, Thiery E et al. Psychiatric diagnosis revisited: towards a system of staging and profiling combining nomothetic and idiographic parameters of momentary mental states. PloS One 2013;8:e59559.
10. Eaton WW, Badawi M, Melton B. Prodromes and precursors: epidemiologic data for primary prevention of disorders with slow onset. Am J Psychiatry 1995;152:967-72.
11. Atkinson AJ, Colburne WA, DeGruttola VG et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
12. Koutsouleris N, Davatzikos C, Bottlender R et al. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. Schizophr Bull 2012;38:1200-15.
13. Berk M, Ng F, Dean O et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008;29:346-51.
14. Yao JK, Keshavan MS. Antioxidants, Redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011;15:2011-35.
15. Depp CA, Mausbach BT, Harmell AL et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord 2012;14:217-26.
16. Fett AK, Viechtbauer W, Dominguez MD et al. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2011;35:573-88.
17. Bartholomeusz CF, Allott K. Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence. Schizophr Res Treat 2012;2012:815315.
18. Brewer WJ, Wood SJ, Phillips LJ et al. Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull 2006;32:538-55.
19. Reichenberg A, Weiser M, Rabinowitz J et al. A populationbased cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry 2002;159:2027-35.
20. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry 2008; 165:579-87.
21. Fusar-Poli P, Deste G, Smieskova R et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012;69:562-71.
22. Seidman LJ, Giuliano AJ, Meyer EC et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010;67:578-88.
23. Mesholam-Gately RI, Giuliano AJ, Goff KP et al. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009;23:315-36.
24. Irani F, Kalkstein S, Moberg EA et al. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull 2011; 37:1318-26.
25. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry 2011;45:93-108.
26. Szoke A, Trandafir A, Dupont ME et al. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 2008; 192:248-57.
27. Green MF, Bearden CE, Cannon TD et al. Social cognition in schizophrenia, Part 1: performance across phase of illness. Schizophr Bull 2012;38:854-64.
28. Arts B, Jabben N, Krabbendam L et al. Meta-analyses of cognitive functioning in euthymic bipolar patients and their firstdegree relatives. Psychol Med 2008;38:771-85.
29. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009;113:1-20.
30. Bora E, Yucel M, Pantelis C et al. Meta-analytic review of neurocognition in bipolar II disorder. Acta Psychiatr Scand 2011;123: 165-74.
31. Elshahawi HH, Essawi H, Rabie MA et al. Cognitive functions among euthymic bipolar I patients after a single manic episode versus recurrent episodes. J Affect Disord 2011;130:180-91.
32. Lopez-Jaramillo C, Lopera-Vasquez J, Gallo A et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010;12:557-67.
33. Torres IJ, DeFreitas VG, DeFreitas CM et al. Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode. J Clin Psychiatry 2010;71:1234-42.
34. Daban C, Martinez-Aran A, Torrent C et al. Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother Psychosom 2006;75:72-84.
35. Gale CR, Batty GD, McIntosh AM et al. Is bipolar disorder more common in highly intelligent people? A cohort study of a million men. Mol Psychiatry 2013;18:190-4.
36. Meyer SE, Carlson GA, Wiggs EA et al. A prospective study of the association among impaired executive functioning, childhood attentional problems, and the development of bipolar disorder. Dev Psychopathol 2004;16:461-76.
37. Ratheesh A, Lin A, Nelson B et al. Neurocognitive functioning in the prodrome of mania - an exploratory study. J Affect Disord 2013;147:441-5.
38. Glahn DC, Almasy L, Barguil M et al. Neurocognitive endophenotypes for bipolar disorder identified in multiplex multigenerational families. Arch Gen Psychiatry 2010;67:168-77.
39. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001;178:200-6.
40. Baune BT, Czira ME, Smith AL et al. Neuropsychological performance in a sample of 13-25 year olds with a history of nonpsychotic major depressive disorder. J Affect Disord 2012;141: 441-8.
41. Douglas KM, Porter RJ. Longitudinal assessment of neuropsychological function in major depression. Aust N Z J Psychiatry 2009;43:1105-17.
42. Gualtieri CT, Johnson LG, Benedict KB. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci 2006;18:217-25.
43. Naismith SL, Hickie IB, Turner K et al. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors. J Clin Exp Neurosci 2003;25: 866-77.
44. Purcell R, Maruff P, Kyrios M et al. Neuropsychological function in young patients with unipolar major depression. Psychol Med 1997;27:1277-85.
45. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 2013;139:81-132.
46. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord 2009;119:1-8.
47. Maalouf FT, Brent D, Clark L et al. Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers. J Affect Disord 2011;133:625-32.
48. Klimes-Dougan B, Ronsaville D, Wiggs EA et al. Neuropsychological functioning in adolescent children of mothers with a history of bipolar or major depressive disorders. Biol Psychiatry 2006;60:957-65.
49. Micco JA, Henin A, Biederman J et al. Executive functioning in offspring at risk for depression and anxiety. Depress Anxiety 2009;26:780-90.
50. Cannon M, Moffitt TE, Caspi A et al. Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: prospective birth cohort study. Br J Psychiatry 2006;189: 463-4.
51. McClintock SM, Husain MM, Greer TL et al. Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. Neuropsychology 2010;24:9-34.
52. Fossati P, Harvey PO, Le Bastard G et al. Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression. J Psychiatr Res 2004;38:137-44.
53. Wood SJ, Yung AR, McGorry PD et al. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol Psychiatry 2011;70:619-25.
54. Boos HB, Aleman A, Cahn W et al. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry 2007;64:297-304.
55. Gogtay N, Vyas NS, Testa R et al. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull 2011;37:504-13.
56. Diwadkar VA, Montrose DM, Dworakowski D et al. Genetically predisposed offspring with schizotypal features: an ultra highrisk group for schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2006;30:230-8.
57. Bhojraj TS, Francis AN, Montrose DM et al. Grey matter and cognitive deficits in young relatives of schizophrenia patients. NeuroImage 2011;54(Suppl. 1):S287-92.
58. Bhojraj TS, Sweeney JA, Prasad KM et al. Gray matter loss in young relatives at risk for schizophrenia: relation with prodromal psychopathology. NeuroImage 2011;54 (Suppl. 1):S272-9.
59. Steen RG, Mull C, McClure R et al. Brain volume in firstepisode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188: 510-8.
60. Borgwardt SJ, McGuire PK, Aston J et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry 2007;191(Suppl. 51):s69-75.
61. Ellison-Wright I, Glahn DC, Laird AR et al. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry 2008;165: 1015-23.
62. Sun D, Phillips L, Velakoulis D et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res 2009;108:85-92.
63. Takahashi T, Wood SJ, Yung AR et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry 2009;66:366-76.
64. Takahashi T, Wood SJ, Soulsby B et al. Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophr Res 2009;108:49-56.
65. Takahashi T, Wood SJ, Yung AR et al. Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. Schizophr Res 2009;111:94-102.
66. McIntosh AM, Owens DC, Moorhead WJ et al. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biol Psychiatry 2011;69:953-8.
67. Vita A, De Peri L, Silenzi C et al. Brain morphology in firstepisode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 2006;82:75-88.
68. Velakoulis D, Wood SJ, Wong MT et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006;63:139-49.
69. Wood SJ, Kennedy D, Phillips LJ et al. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. NeuroImage 2010;52:62-8.
70. Buehlmann E, Berger GE, Aston J et al. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. J Psychiatr Res 2010;44:447-53.
71. Olabi B, Ellison-Wright I, McIntosh AM et al. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry 2011; 70:88-96.
72. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008;34:354-66.
73. Ho BC, Andreasen NC, Ziebell S et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of firstepisode schizophrenia. Arch Gen Psychiatry 2011;68:128-37.
74. Andreasen NC, Liu D, Ziebell S et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013;170:609-15.
75. Arnone D, Cavanagh J, Gerber D et al. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: metaanalysis. Br J Psychiatry 2009;195:194-201.
76. Usher J, Leucht S, Falkai P et al. Correlation between amygdala volume and age in bipolar disorder - a systematic review and meta-analysis of structural MRI studies. Psychiatry Res 2010; 182:1-8.
77. Vita A, De Peri L, Sacchetti E. Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies. Bipolar Disord 2009;11:807-14.
78. Hickie IB, Naismith SL, Ward PB et al. Psychomotor slowing in older patients with major depression: relationships with blood flow in the caudate nucleus and white matter lesions. Psychiatry Res 2007;155:211-20.
79. Kalmar JH, Wang F, Spencer L et al. Preliminary evidence for progressive prefrontal abnormalities in adolescents and young adults with bipolar disorder. J Int Neuropsychol Soc 2009;15: 476-81.
80. Salokangas RK, Cannon T, Van Erp T et al. Structural magnetic resonance imaging in patients with first-episode schizophrenia, psychotic and severe non-psychotic depression and healthy controls. Results of the schizophrenia and affective psychoses (SAP) project. Br J Psychiatry 2002;181(Suppl. 43):s58-65.
81. Ketter TA, Wang PW, Becker OV et al. Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia? J Psychiatr Res 2004;38:47-61.
82. Strasser HC, Lilyestrom J, Ashby ER et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot study. Biol Psychiatry 2005;57:633-9.
83. De Peri L, Crescini A, Deste G et al. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a metaanalysis of controlled magnetic resonance imaging studies. Curr Pharmaceut Des 2012;18:486-94.
84. Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr Res 2010;117:1-12.
85. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005;76:1-23.
86. Umbricht D, Koller R, Schmid L et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry 2003;53:1120-31.
87. He W, Chai H, Zheng L et al. Mismatch negativity in treatmentresistant depression and borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:366-71.
88. Kahkonen S, Yamashita H, Rytsala H et al. Dysfunction in early auditory processing in major depressive disorder revealed by combined MEG and EEG. J Psychiatry Neurosci Jpn 2007;32: 316-22.
89. Chang Y, Xu J, Shi N et al. Dysfunction of processing taskirrelevant emotional faces in major depressive disorder patients revealed by expression-related visual MMN. Neurosci Lett 2010; 472:33-7.
90. Takei Y, Kumano S, Hattori S et al. Preattentive dysfunction in major depression: a magnetoencephalography study using auditory mismatch negativity. Psychophysiology 2009;46:52-61.
91. Jahshan C, Cadenhead KS, Rissling AJ et al. Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med 2012;42:85-97.
92. Ahveninen J, Jaaskelainen IP, Osipova D et al. Inherited auditory-cortical dysfunction in twin pairs discordant for schizophrenia. Biol Psychiatry 2006;60:612-20.
93. Magno E, Yeap S, Thakore JH et al. Are auditory-evoked frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic schizophrenia. Biol Psychiatry 2008;64:385-91.
94. Bodatsch M, Ruhrmann S, Wagner M et al. Prediction of psychosis by mismatch negativity. Biol Psychiatry 2011;69:959-66.
95. Devrim-Ucok M, Keskin-Ergen HY, Ucok A. Mismatch negativity at acute and post-acute phases of first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008;258:179-85.
96. Salisbury DF, Shenton ME, Griggs CB et al. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch Gen Psychiatry 2002;59:686-94.
97. Salisbury DF, Kuroki N, Kasai K et al. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 2007;64:521-9.
98. Todd J, Michie PT, Schall U et al. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry 2008;63:58-64.
99. Umbricht DS, Bates JA, Lieberman JA et al. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry 2006;59:762-72.
100. Valkonen-Korhonen M, Purhonen M, Tarkka IM et al. Altered auditory processing in acutely psychotic never-medicated firstepisode patients. Brain Res Cogn Brain Res 2003;17:747-58.
101. Rasser PE, Schall U, Todd J et al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr Bull 2011;37:131-40.
102. Oades RD, Wild-Wall N, Juran SA et al. Auditory change detection in schizophrenia: sources of activity, related neuropsychological function and symptoms in patients with a first episode in adolescence, and patients 14 years after an adolescent illnessonset. BMC Psychiatry 2006;6:7.
103. Shaikh M, Valmaggia L, Broome MR et al. Reduced mismatch negativity predates the onset of psychosis. Schizophr Res 2012; 134:42-8.
104. Shin KS, Kim JS, Kang DH et al. Pre-attentive auditory processing in ultra-high-risk for schizophrenia with magnetoencephalography. Biol Psychiatry 2009;65:1071-8.
105. Hermens DF, Ward PB, Hodge MA et al. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:822-9.
106. Glozier N, Martiniuk A, Patton G et al. Short sleep duration in prevalent and persistent psychological distress in young adults: the DRIVE study. Sleep 2010;33:1139-45.
107. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011; 378:621-31.
108. Angst J, Merikangas KR. Multi-dimensional criteria for the diagnosis of depression. J Affect Disord 2001;62:7-15.
109. Keshavan MS, Reynolds CF, Kupfer DJ. Electroencephalographic sleep in schizophrenia: a critical review. Compr Psychiatry 1990;31:34-47.
110. Rao U, Hammen CL, Poland RE. Risk markers for depression in adolescents: sleep and HPA measures. Neuropsychopharmacology 2009;34:1936-45.
111. Keshavan MS, Diwadkar VA, Montrose DM et al. Premorbid characterization in schizophrenia: the Pittsburgh High Risk Study. World Psychiatry 2004;3:163-8.
112. Sarkar S, Katshu MZ, Nizamie SH et al. Slow wave sleep deficits as a trait marker in patients with schizophrenia. Schizophr Res 2010;124:127-33.
113. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010;67:241-51.
114. Poulin J, Daoust AM, Forest G et al. Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia. Schizophr Res 2003;62:147-53.
115. Keshavan MS, Miewald J, Haas G et al. Slow-wave sleep and symptomatology in schizophrenia and related psychotic disorders. J Psychiatr Res 1995;29:303-14.
116. Keshavan MS, Reynolds CF III, Miewald JM et al. A longitudinal study of EEG sleep in schizophrenia. Psychiatry Res 1996; 59:203-11.
117. Phillips LJ, McGorry PD, Garner B et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006;40:725-41.
118. Zhang TY, Labonte B, Wen XL et al. Epigenetic mechanisms for the early environmental regulation of hippocampal glucocorticoid receptor gene expression in rodents and humans. Neuropsychopharmacology 2013;38:111-23.
119. Watson S, Gallagher P, Ritchie JC et al. Hypothalamic-pituitaryadrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496-502.
120. Pariante CM, Dazzan P, Danese A et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005;30:1923-31.
121. Ryan MC, Sharifi N, Condren R et al. Evidence of basal pituitaryadrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004;29:1065-70.
122. Myin-Germeys I, Delespaul P, van Os J. Behavioural sensitization to daily life stress in psychosis. PsycholMed 2005;35:733-41.
123. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 2000;48:1121-32.
124. Garner B, Phassouliotis C, Phillips LJ et al. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J Psychiatr Res 2011;45:249-55.
125. Mondelli V, Pariante CM, Navari S et al. Higher cortisol levels are associated with smaller left hippocampal volume in firstepisode psychosis. Schizophr Res 2010;119:75-8.
126. Aas M, Dazzan P, Mondelli V et al. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychol Med 2011;41:463-76.
127. Cohrs S, Roher C, Jordan W et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 2006;185:11-8.
128. Nicolo JP, Berger GE, Garner BA et al. The effect of atypical antipsychotics on pituitary gland volume in patients with firstepisode psychosis: a longitudinal MRI study. Schizophr Res 2010;116:49-54.
129. Garner B, Pariante CM, Wood SJ et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005;58:417-23.
130. Walker EF, Brennan PA, Esterberg M et al. Longitudinal changes in cortisol secretion and conversion to psychosis in atrisk youth. J Abnorm Psychol 2010;119:401-8.
131. Thompson KN, Phillips LJ, Komesaroff P et al. Stress and HPAaxis functioning in young people at ultra high risk for psychosis. J Psychiatr Res 2007;41:561-9.
132. Collip D, Nicolson NA, Lardinois M et al. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. Psychol Med 2011;41:2305-15.
133. Mondelli V, Dazzan P, Gabilondo A et al. Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder. Psychoneuroendocrinology 2008;33:1004-12.
134. McNutt MD, Liu S, Manatunga A et al. Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 2012;37:1444-54.
135. Miller BJ, Buckley P, Seabolt W et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-71.
136. Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011;24:519-25.
137. Wadee AA, Kuschke RH, Wood LA et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 2002;17:175-9.
138. Do KQ, Cabungcal JH, Frank A et al. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009; 19:220-30.
139. Pasco JA, Jacka FN, Williams LJ et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010;79:323-5.
140. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1355-61.
141. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brainderived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009;12:447-58.
142. Andreazza AC. Mitchondrial dysfunction and oxidative stress in bipolar disorder. Eur Psychiatry 2009;24:S15.
143. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:804-17.
144. Moylan S, Maes M, Wray NR et al. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18:595-606.
145. Goldstein BI, Kemp DE, Soczynska JK et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078-90.
146. Meyer JM, McEvoy JP, Davis VG et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 2009;66:1013-22.
147. Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23:87-94.
148. Muller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, doubleblind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121:118-24.
149. Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011;72:1229-35.
150. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci Jpn 2011;36:78-86.
151. Laan W, Grobbee DE, Selten JP et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71:520-7.
152. Stolk P, Souverein PC, Wilting I et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostagland Leukotr Essent Fatty Acids 2010;82: 9-14.
153. Dean OM, Data-Franco J, Giorlando F et al. Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012;26:391-401.
154. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 2008;233:674-88.
155. Horrobin DF. Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase. Hum Psychopharmacol 2001;16:45-52.
156. Parker G, Gibson NA, Brotchie H et al. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006;163:969-78.
157. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998;30:193-208.
158. Assies J, Pouwer F, Lok A et al. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PloS One 2010;5:e10635.
159. McNamara RK, Jandacek R, Rider T et al. Fatty acid composition of the postmortem prefrontal cortex of adolescent male and female suicide victims. Prostagland Leukotr Essent Fatty Acids 2009;80:19-26.
160. Ng F, Berk M, Dean O et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11:851-76.
161. Hoen WP, Lijmer JG, Duran M et al. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res 2013;207:1-12.
162. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463-93.
163. Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Develop 2004; 44:273-82.
164. Hedelin M, Lof M, Olsson M et al. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population. BMC Psychiatry 2010;10:38.
165. Amminger GP, Schafer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54.
166. Amminger GP, Schafer MR, Klier CM et al. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in helpseeking ultra-high-risk individuals. Mol Psychiatry 2012;17: 1150-2.
167. Nasrallah H. Beyond dopamine: the "other" effects of antipsychotics. Curr Psychiatry 2013;12:8-9.
168. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 2012;32:179-85.
169. Assies J, Lieverse R, Vreken P et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001; 49:510-22.
170. Peters BD, Machielsen MW, Hoen WP et al. Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophr Bull 2013;39:830-8.
171. Berger GE, Smesny S, Amminger GP. Bioactive lipids in schizophrenia. Int Rev Psychiatry 2006;18:85-98.
172. Smesny S, Kinder D, Willhardt I et al. Increased calciumindependent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol Psychiatry 2005;57:399-405.
173. Smesny S, Milleit B, Hipler UC et al. Omega-3 fatty acid supplementation changes intracellular phospholipase A activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol Psychiatry 2014;19:317-24.
174. Insel T, Cuthbert B, Garvey M et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010;167:748-51.